In one of the early successes in breast cancer combination therapy, the addition of the anti-HER2 monoclonal antibody trastuzumab significantly increased the benefits of first-line chemotherapy in patients with HER2-overexpressing metastatic breast cancer [88]. This evidence concerns the gene ERBB2 and breast cancer.